Results 11 to 20 of about 8,771 (219)

Upadacitinib effectiveness and factors associated with minimal disease activity achievement in patients with psoriatic arthritis: preliminary data of a real-life multicenter study [PDF]

, 2023
Background: Upadacitinib (UPA) is a selective JAK inhibitor recently approved for the treatment of psoriatic arthritis (PsA). In this post-approval study, we aimed to evaluate the effectiveness and safety of UPA over 24 weeks and identify clinical ...
Benfaremo D., Boffini N., Carletto A., Chimenti M. S., Ciccia F., Dagna L., Giovannini I., Luchetti Gentiloni M. M., Luciano N., Moroncini G., Paci V., Pantano I., Piccinelli A., Possemato N., Ramonda R., Salvarani C., Sandri G., Selmi C., Striani G., Zabotti A.   +19 more
core   +1 more source

Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]

, 2019
Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran, Meier, Katharina, Solimani, Farzan   +2 more
core   +1 more source

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

RMD Open, 2022
Introduction Long-term safety and efficacy of upadacitinib in patients with active ankylosing spondylitis (AS) has not been previously reported.Methods In SELECT-AXIS 1, patients receiving placebo were switched to upadacitinib 15 mg once daily at week 14
Désirée van der Heijde, Filip van den Bosch, Atul Deodhar, Joachim Sieper, Bernard Combe, Walter P Maksymowych, In-Ho Song, Tae-Hwan Kim, Mitsumasa Kishimoto, Yuanyuan Duan, Yunxia Sui, Andrew J Östör, Peter K Wung   +12 more
doaj   +1 more source

HiJAKing innate lymphoid cells? [PDF]

, 2017
The family of innate lymphoid cells (ILCs) consists of a heterogeneous group of cytokine-producing cells that have features in common with adaptive T helper (Th) cells.
Gadina, Massimo, Le, Mimi T, Sciume', Giuseppe   +2 more
core   +1 more source

The Cardiovascular Effects of a Meal: J-Tpeak and Tpeak -Tend Assessment and Further Insights Into the Physiological Effects. [PDF]

, 2019
Meal intake leads to a significant and prolonged increase in cardiac output to supply the splanchnic vasculature. A meal is associated with sympathetic activation of the cardiovascular system, and food ingestion is correlated with an increase in heart ...
Camm, AJ, Del Bianco, T, Djumanov, D, Ferber, G, Fernandes, S, Graff, C, Kanters, JK, Täubel, J, Van Langenhoven, L   +8 more
core   +2 more sources

Utilization of data below the analytical limit of quantitation in pharmacokinetic analysis and modeling: promoting interdisciplinary debate [PDF]

, 2018
Traditionally, bioanalytical laboratories do not report actual concentrations for samples with results below the LOQ (BLQ) in pharmacokinetic studies.
Atholl Johnston, Autmizguine J, Beal S, Charlotte I S Barker, Chen X, Denti P, European Medicines Agency, Gopalakrishnan S, Hanno Evard, Ivo Leito, Jitmuang A, Joseph F Standing, Kalev Takkis, Karin Kipper, Keizer RJ, Klünder B, Koit Herodes, Lewis Couchman, Max Hecht, Ministry of Health Labour and Welfare, NordVal, Organisation for Economic Co-operation and Development, Pires de Mello CP, Rūta Veigure, US FDA, van der Laan LE, van Kesteren C, Worm AM   +27 more
core   +1 more source

Comparative short-term efficacy of upadacitinib versus tofacitinib for ulcerative colitis: a 24-week real-world study in Japan [PDF]

Intestinal Research
Background/Aims Tofacitinib and upadacitinib are small-molecule compounds that inhibit the Janus kinase pathway for the treatment of refractory ulcerative colitis.
Akiko Tamura, Hiromichi Shimizu, Toshimitsu Fujii, Ami Kawamoto, Ryo Morikawa, Shuji Hibiya, Kento Takenaka, Masakazu Nagahori, Kazuo Ohtsuka, Ryuichi Okamoto   +9 more
doaj   +1 more source

Janus kinase inhibitors: a new tool for the treatment of axial spondyloarthritis [PDF]

, 2023
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease involving the spine, peripheral joints, and entheses. This condition causes stiffness, pain, and significant limitation of movement.
Accapezzato D., Caccavale R., Paroli M., Paroli M. P., Spadea L.   +4 more
core   +1 more source

A phase 3 randomized, multicenter, double-blind study to evaluate the safety of upadacitinib in combination with topical corticosteroids in adolescent and adult patients with moderate-to-severe atopic dermatitis in Japan (Rising Up): An interim 24-week analysisCapsule Summary

JAAD International, 2022
Background: Systemic atopic dermatitis treatments that have acceptable safety are needed. Objective: To evaluate the safety of the oral Janus kinase inhibitor upadacitinib in combination with topical corticosteroids (TCSs) for the treatment of atopic ...
Norito Katoh, MD, PhD, Yukihiro Ohya, MD, PhD, Hiroyuki Murota, MD, PhD, Masanori Ikeda, MD, PhD, Xiaofei Hu, PhD, Kimitoshi Ikeda, PhD, John Liu, MD, MS, Takuya Sasaki, Alvina D. Chu, MD, Henrique D. Teixeira, PhD, MBA, Hidehisa Saeki, MD, PhD   +10 more
doaj   +1 more source

Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response : efficacy and safety in patients with rheumatoid arthritis [PDF]

, 2021
Objectives To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or vice versa, in patients with rheumatoid arthritis with non-response or incomplete-response to the initial therapy.
Bessette, Louis, Blanco, Ricardo, DeMasi, Ryan, Enejosa, Jeffrey, Fleischmann, Roy M., Hall, Stephen, Li, Yihan, Song, In-Ho, Song, Yanna, Thomson, Glen T. D., Van den Bosch, Filip, Zerbini, Cristiano   +11 more
core   +1 more source